Optimization of B Cell Responses in Human Immune System Mice Through Organoid Based Screening.

Publication date: Jun 26, 2026

B cells in the human immune system (HIS) mice exhibit weak responses to external antigens, characterized by insufficient antigen-specific B cell proliferation, low antibody titers, and a lack of differentiation into effector B cell subsets. We hypothesize that this failure is due to the absence of second signals provided by T cells following BCR stimulation. To address this, we developed an organoid screening system using HIS mouse splenocytes to identify missing signals. A combination of IL-4, IL-10, IL-21 together with CD40L was found to drive potent B cell proliferation and differentiation. Further organoid-based screening revealed that TNF-α and CpG synergistically promoted IgG class-switch, and that temporal separation of expansion and differentiation signals enhanced B cell responses. Translating these findings in vivo, CpG-adjuvanted vaccination followed by sequential i. v. delivery of expansion and differentiation cytokine mixtures induced antigen-specific B cell expansion, B cell differentiation, and IgG class-switch in HIS mice without affecting non-specific B cells. Sorting RBD-specific B cells from immunized mice yielded recombinant antibodies with high binding affinity and neutralizing activity against SARS-CoV-2 pseudovirus. Our study establishes a spleen organoid platform for screening factors that influence B cell responses in HIS mice and provides a generalizable strategy to obtain fully human antibodies for therapeutic development.

Open Access PDF

Concepts Keywords
Absence antibody development
Cd40l B cells
Class cytokines
Pseudovirus vaccines
Vaccination

Semantics

Type Source Name
pathway REACTOME Immune System
drug DRUGBANK Binetrakin
drug DRUGBANK Interleukin-10
drug DRUGBANK Coenzyme M
disease MESH NOD
drug DRUGBANK Pinaverium
pathway REACTOME Reproduction
disease MESH face
drug DRUGBANK Tretamine
disease MESH ead
disease MESH PBS
disease MESH included
drug DRUGBANK Cycloserine
disease MESH DCs
pathway REACTOME Apoptosis
disease MESH dis
drug DRUGBANK Trestolone
disease MESH body weight
disease MESH weight loss
drug DRUGBANK Indoleacetic acid
disease MESH CDR3
disease MESH dissociation
pathway REACTOME TNF signaling
disease MESH strains
disease MESH inflammation
disease MESH syndromes
disease MESH FDC
drug DRUGBANK Nevirapine
disease MESH FBS
drug DRUGBANK Amino acids
drug DRUGBANK Streptomycin
drug DRUGBANK Biotin
drug DRUGBANK Aluminum hydroxide
drug DRUGBANK Water
drug DRUGBANK Aspartame
disease MESH APC
disease MESH NHS
drug DRUGBANK Edetic Acid
drug DRUGBANK Immune Globulin Human
drug DRUGBANK Serine
drug DRUGBANK Tromethamine
drug DRUGBANK Glycine
disease MESH infection
disease MESH cancer
disease MESH Ito
pathway REACTOME Adaptive Immune System
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH Allergy
drug DRUGBANK Risedronate
disease MESH COVID 19
disease MESH Post COVID Conditions
drug DRUGBANK Guanosine
disease MESH pDC
drug DRUGBANK Carboxyamidotriazole
pathway REACTOME Signal Transduction
disease MESH STAR
disease MESH Viral Infection

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *